What question did this study set out to answer?

To evaluate the economic impact and clinical outcomes of disease-activity-guided dose reduction of IL-17 and IL-23 inhibitors in adults with stable plaque psoriasis.

July 31, 2026Dermatology Practical & ConceptualOpen Access

Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors

View Full Paper

Ask AI

Bookmark

Authors

ECEdoardo Cammarata CAChiara Airoldi JCJacopo Colombo

Discussion

Member takes

Overview

Prospective open-label study demonstrates that extending biologic dosing intervals lowers costs in stable plaque psoriasis, indicating sustainable long-term treatment feasibility.

Key Points

To evaluate the economic impact and clinical outcomes of disease-activity-guided dose reduction of IL-17 and IL-23 inhibitors in adults with stable plaque psoriasis.
Conducted a cost analysis nested in the multicenter prospective open-label PSORED trial in Piedmont, Italy (2023–2025) involving 156 adults with stable plaque psoriasis (PASI ≤3 and DLQI ≤3 for ≥9 months).
Evaluated a dose reduction protocol extending maintenance intervals 1.5-fold for secukinumab, brodalumab, guselkumab, and risankizumab compared to standard dosing over a 52-week horizon.
Dose reduction generated a 26% decrease in total direct healthcare costs, yielding an average annual saving of €7,303.57 per patient without increasing routine follow-up visits.
Of the 156 participants, 39 discontinued the reduced-dose regimen (38 resumed standard dosing and one switched therapy), while overall disease control was preserved.

Cite This Study

Cammarata et al. (2026) studied this question.

synapsesocial.com/papers/6a785a3ed3a6aa87c6be3bba https://doi.org/10.5826/dpc.1603a6747

View Full Paper

Ask AI

Bookmark

July 31, 2026Dermatology Practical & ConceptualOpen Access

Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors

View Full Paper

Ask AI

Bookmark

Authors

ECEdoardo Cammarata CAChiara Airoldi JCJacopo Colombo

Discussion

Member takes

Overview

Prospective open-label study demonstrates that extending biologic dosing intervals lowers costs in stable plaque psoriasis, indicating sustainable long-term treatment feasibility.

Key Points

To evaluate the economic impact and clinical outcomes of disease-activity-guided dose reduction of IL-17 and IL-23 inhibitors in adults with stable plaque psoriasis.
Conducted a cost analysis nested in the multicenter prospective open-label PSORED trial in Piedmont, Italy (2023–2025) involving 156 adults with stable plaque psoriasis (PASI ≤3 and DLQI ≤3 for ≥9 months).
Evaluated a dose reduction protocol extending maintenance intervals 1.5-fold for secukinumab, brodalumab, guselkumab, and risankizumab compared to standard dosing over a 52-week horizon.
Dose reduction generated a 26% decrease in total direct healthcare costs, yielding an average annual saving of €7,303.57 per patient without increasing routine follow-up visits.
Of the 156 participants, 39 discontinued the reduced-dose regimen (38 resumed standard dosing and one switched therapy), while overall disease control was preserved.

Cite This Study

Cammarata et al. (2026) studied this question.

synapsesocial.com/papers/6a785a3ed3a6aa87c6be3bba https://doi.org/10.5826/dpc.1603a6747

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark